HOME >> BIOLOGY >> NEWS
Nabi experimental vaccine reduced Staph aureus bloodstream infections by nearly 60 percent

Phase 3 study results published in the New England Journal of Medicine

Patients with compromised immune systems benefit significantly

Rockville, MD, Feb. 13, 2002 A single injection of a first-of-its-kind experimental vaccine, Nabi(tm) StaphVAX(tm)(S. aureus polysaccharide conjugate vaccine), reduced bloodstream infections caused by the often drug-resistant and potentially deadly bacteria, Staphylococcus aureus, in end-stage kidney disease patients by nearly 60 percent, according to a phase 3 study that appears in the February 14th issue of The New England Journal of Medicine. The study was conducted by investigators from Kaiser Permanente in collaboration with scientists at the National Institutes of Health (NIH) and at Nabi (Nasdaq: NABI).

Staphylococcus aureus is a major cause of hospital-acquired infections, including bloodstream infections, or bacteremias. Community-acquired Staph infections are also of growing concern. Staph is one of the most frequent and potentially deadly bacterial infections in hospitals today. Now, for the first time, an experimental vaccine has been shown to reduce the incidence of bloodstream infections caused by this bacteria, says co-author Robert Naso, Ph.D., senior vice president of quality, regulatory and product development at Nabi, the biopharmaceutical company that is developing the vaccine and supported the study.

After just one injection, StaphVAX reduced the incidence of systemic S. aureus infection in the blood by 57 percent, through 40 weeks of the 54-week study. By the end of the study, 86 percent of the patients had responded to the candidate vaccine with high levels of specific antibody.

Kidney disease patients on hemodialysis are among the least likely to respond to a vaccine because their immune systems are generally compromised. Based upon previous clinical studies in normal, healthy volunteers, we believe that other patient populations at ris
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
13-Feb-2002


Page: 1 2 3 4 5

Related biology news :

1. Stop leak solution found for toxicity problems in experimental gene therapy
2. Finding a Holy Grail: simulated and experimental protein folding compares nicely
3. Scientists clear hurdle in effort to destroy experimental brain cancers with viruses
4. NIAID launches major step in trial of experimental shingles vaccine
5. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
6. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
7. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
8. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
9. Protective gene may enhance vaccine responses
10. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
11. New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, ... company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility ...
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance ... a successful study, while protecting and accessing the catheter or device post-surgery is often ... Envigo in a live webinar on Wednesday, August 5, 2020 ...
(Date:7/18/2020)... DAYTON, Ohio (PRWEB) , ... July 16, 2020 ... ... clinical data solutions to aid in the early detection and prevention of high-burden ... partnership to enable US-based hospitals and healthcare organizations to utilize existing data in ...
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
Breaking Biology Technology:
Cached News: